CTI BioPharma Corp. (NASDAQ:CTIC) – Jefferies Group issued their Q3 2017 EPS estimates for shares of CTI BioPharma Corp. in a research report issued on Tuesday. Jefferies Group analyst M. Andrews forecasts that the biopharmaceutical company will post earnings of ($0.32) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $7.50 target price on the stock. Jefferies Group also issued estimates for CTI BioPharma Corp.’s Q4 2017 earnings at ($0.31) EPS, FY2017 earnings at ($1.26) EPS, Q1 2018 earnings at ($0.32) EPS, Q2 2018 earnings at ($0.31) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.55) EPS, FY2018 earnings at ($1.87) EPS, FY2019 earnings at ($0.71) EPS, FY2020 earnings at ($0.25) EPS and FY2021 earnings at $0.26 EPS.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/15/cti-biopharma-corp-ctic-expected-to-post-q3-2017-earnings-of-0-32-per-share.html.
Shares of CTI BioPharma Corp. (NASDAQ CTIC) opened at 3.32 on Thursday. The firm’s market cap is $105.33 million. CTI BioPharma Corp. has a 12 month low of $0.36 and a 12 month high of $6.48. The stock has a 50 day moving average of $3.34 and a 200 day moving average of $3.77.
CTI BioPharma Corp. (NASDAQ:CTIC) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative net margin of 136.76% and a negative return on equity of 418.99%. The business had revenue of $22.23 million for the quarter.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Segantii Capital Management Ltd acquired a new stake in CTI BioPharma Corp. in the 1st quarter valued at about $102,000. WASHINGTON TRUST Co acquired a new stake in CTI BioPharma Corp. in the 2nd quarter valued at about $104,000. Acadian Asset Management LLC acquired a new stake in CTI BioPharma Corp. in the 1st quarter valued at about $181,000. Stonepine Capital Management LLC acquired a new stake in CTI BioPharma Corp. in the 2nd quarter valued at about $7,561,000. Finally, Nine Chapters Capital Management LLC grew its stake in CTI BioPharma Corp. by 152.9% in the 1st quarter. Nine Chapters Capital Management LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 26,300 shares during the last quarter. 42.87% of the stock is currently owned by hedge funds and other institutional investors.
About CTI BioPharma Corp.
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.